Introduction:
Eligo Bioscience has secured $30m in a series B funding round to further develop its gene-editing solutions targeting diseases associated with bacterial genes within the human microbiome. The funding will be used to advance the development of EB005, Eligo’s program targeting acne vulgaris, and to expand into other chronic diseases, including oncology. Eligo Bioscience’s unique approach aims to accurately modify genetic elements within the human microbiome, offering potential advancements in the treatment of various chronic and life-threatening diseases.
- Eligo Bioscience has secured $30m in a series B funding round led by Sanofi Ventures.
- The funding will be used to develop EB005, Eligo’s program targeting acne vulgaris, and expand into other chronic diseases, including oncology.
- Eligo Bioscience’s approach allows for accurate modification of genetic elements within the human microbiome, providing potential advancements in treating chronic and life-threatening diseases.
- The funding signifies Eligo Bioscience’s evolution into a clinical-stage biotech company.
- Eligo Bioscience aims to make significant advancements in treating diseases by editing the genetic makeup of the human microbiome.
Conclusion:
Eligo Bioscience’s securing of $30m in funding will support the development of innovative gene-editing solutions for diseases associated with bacterial genes within the human microbiome. This funding will enable the company to advance its program targeting acne vulgaris and expand into other chronic diseases, potentially revolutionizing the treatment of various conditions. Eligo Bioscience’s unique approach offers accurate modification of genetic elements within the human microbiome, paving the way for advancements in the field of genetic medicine.
